Shares of Replimune Group Inc. (REPL), Snowflake Inc. (SNOW), and Cloudflare Inc. (NET) shares surged to annual highs on Friday last week amid a series of positive company catalysts, Wall Street optimism, and earnings anticipation.REPL stock surged about 107% at close after an independent panel of…
Replimune Group (REPL) drew renewed investor attention after the biotech company received a major boost from a favorable U.S. Food and Drug Administration (FDA) advisory committee review of its melanoma therapy RP1, prompting Cantor Fitzgerald to upgrade the stock to ‘Overweight’ from ‘Neutral’.At…
Replimune Group, Inc. (REPL) said on Thursday that an independent panel of experts advising the U.S. Food and Drug Administration voted in favor of its experimental treatment for advanced melanoma.The Massachusetts-based biotechnology company announced the favorable outcome following a meeting of t…
Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningfulWOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. NASDAQ:REPL, a clinical-stage biotechnology company pioneering the development of novel oncolytic immunother…
Shares of Replimune (REPL) crashed nearly 32% on Tuesday after its lead skin cancer therapy came under fresh scrutiny, with U.S. Food and Drug Administration staff reviewers stating the company has not provided clear evidence that the drug works as claimed.The concerns were outlined in briefing doc…
